- Biolase Inc (NASDAQ:BIOL) shares are trading higher on strong volume after it reported Q2 sales of $9.1 million, +211% Y/Y, edging out a consensus of $8.31 million.
- Over 70% of U.S. laser sales came from new customers, continuing a positive trend, and more than 35% of U.S. Waterlase sales came from dental specialists.
- Net revenue was 6% higher than the pre-pandemic revenues during the second quarter of 2019.
- U.S. and international revenue increased 167% and 340%, respectively, as more dental practices were operating during Q2 than Q2 FY20 due to the pandemic.
- Laser system sales increased 424%. Consumables and other revenue increased 173%.
- The gross margin expanded to 44% from 32% a year ago due to higher revenue, favorable revenue mix, and higher average selling prices.
- During Q2, Biolase was able to break even compared to an EPS loss of $(0.12) a year ago. Cash and cash equivalents totaled $37.1 million.
- Biolase forecasts Q3 revenue to be significantly above Q3 FY20 despite the pent-up demand it experienced in last year's Q3 as procedure volume dramatically improved from historically low levels in the 2020 second quarter.
- Price Action: BIOL shares are up 31.4% at $0.83 during the market session on the last check Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments